Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is a Healthcare company (Biotechnology) with a market capitalization of $260M. The Maz Rating grades it against the other companies in its sector.
Enanta Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $8.93, Enanta Pharmaceuticals, Inc. trades at 4.9x sales and 3.9x book value. Over the last twelve months it generated about $53M of revenue and a net loss of $50M. It runs a gross margin of -84.4%, an operating margin of -99.0% and a net margin of -108.3%. It shows return on equity of -64.3%, return on invested capital of -27.6% and a free cash flow yield of -11.9%. On the balance sheet: a debt-to-equity ratio of 0.68 and a current ratio of 3.78. Over the past 52 weeks the share price ranged from $8.81 to $17.15, with a beta of 0.96.
Enanta Pharmaceuticals, Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 14 Buy, 3 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.